Hodgkin‐Inflammatory‐Based Model ME‐IPS Is a New Inflammatory‐Based Prognostic Model Calculated at Diagnosis: Results From a Real‐Life Study
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70066 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Andrea Duminuco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology With BMT Unit, A.O.U. "G. Rodolico-San Marco", Catania, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Neoplasm Staging, Clinical Decision Rules. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Identifying patients with a higher risk of recidivate/refractory Hodgkin lymphoma (R/R HL) is a challenge that needs to be addressed. The International Prognostic System (IPS) identifies patients with a poor prognosis in advanced stages, although its relevance has decreased due to advancements in modern treatment. The interim PET‐2 scan after two chemotherapy cycles is now considered the most crucial prognostic tool, but it is only available after treatment initiation.
Methods
We investigate the role of clinical and inflammatory indices associated with clinical data in 212 HL patients, focusing on peripheral blood ratios.
Results
During follow‐up, after a median of 60 months [3–213], 157 patients (74.1%) were in complete remission, and 55 were classified as R/R. SII (platelets × neutrophils/lymphocytes) ≥ 270, IgM < 50 mg/dL, male gender, and extranodal localization correlate with higher relapse and refractory rates. Assigning one point to each variable, a new prognostic score (ME‐IPS) was developed, recognizing three risk classes. A total of 135 (63.7%) patients belonged to the low‐risk class (0–1 points), 55 (25.9%) to intermediate (2 points), and 22 (10.4%) to high (3–4 points). The median PFS for the three groups was statistically different (not achieved vs. 89 vs. 8.8 months, p < 0.001), with a 5‐year cut‐off of 83%, 67%, and 27% ( p < 0.001). ME‐IPS, validated against the traditional IPS, performs better in identifying high‐risk patients with data collected at diagnosis.
Conclusion
Combining the ME‐IPS model with PET‐2 may provide a more effective tool for HL prognosis, particularly in cases of advanced disease, and guide treatment decisions in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology With BMT Unit, A.O.U. "G. Rodolico-San Marco", Catania, Italy.
- Faculty of Medicine and Surgery, "Kore" University of Enna, Enna, Italy.
- Dipartimento di Specialità Medico-Chirurgiche, CHIRMED, University of Catania, Catania, Italy.
- Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
ORCID-Profile: Andrea Duminuco
Zitieren
APA
Duminuco, A., Del Fabro, V., Santuccio, G., Chiarenza, A., Caruso, A. L., Figuera, A., Motta, G., Fiumara, P. F., Petronaci, A., Palumbo, F., Di Raimondo, F., Palumbo, G. A., & Romano, A. (2026). Hodgkin‐Inflammatory‐Based Model ME‐IPS Is a New Inflammatory‐Based Prognostic Model Calculated at Diagnosis: Results From a Real‐Life Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70066
Vancouver
Duminuco A, Del Fabro V, Santuccio G, Chiarenza A, Caruso AL, Figuera A, et al. Hodgkin‐Inflammatory‐Based Model ME‐IPS Is a New Inflammatory‐Based Prognostic Model Calculated at Diagnosis: Results From a Real‐Life Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70066
BibTeX
@article{Duminuco2026,
author = {Duminuco, Andrea and Del Fabro, Vittorio and Santuccio, Gabriella and Chiarenza, Annalisa and Caruso, Anastasia Laura and Figuera, Amalia and Motta, Giovanna and Fiumara, Paolo Fabio and Petronaci, Alessandro and Palumbo, Fanny and Di Raimondo, Francesco and Palumbo, Giuseppe Alberto and Romano, Alessandra},
title = {Hodgkin‐Inflammatory‐Based Model ME‐IPS Is a New Inflammatory‐Based Prognostic Model Calculated at Diagnosis: Results From a Real‐Life Study},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70066}
}
EUVIMED